恩扎卢胺联合ADT在不同转移模式mHSPC中的疗效:ARCHES事后分析
ARCHES研究事后分析评估转移模式对恩扎卢胺联合雄激素剥夺治疗(ADT)疗效的影响。入组1146例转移性激素敏感性前列腺癌患者,按基线影像转移模式分组。结果显示,恩扎卢胺联合ADT在仅骨转移(HR 0.33)和骨+淋巴结转移(HR 0.31)亚组中显著降低影像学进展风险,但在内脏转移患者中可能疗效较差。
要点
- 恩扎卢胺联合ADT显著改善仅骨转移和骨+淋巴结转移患者的影像学无进展生存。
- 仅骨转移亚组影像学进展风险HR为0.33,骨+淋巴结转移亚组HR为0.31。
- 内脏转移患者可能从恩扎卢胺联合ADT中获益较少。
核心结论
- 恩扎卢胺联合ADT可改善骨和/或淋巴结转移的mHSPC患者结局,但对内脏转移模式可能疗效较差。
研究设计与样本
- ARCHES(NCT02677896)随机对照研究的事后分析,纳入1146例转移性激素敏感性前列腺癌患者,按1:1随机接受恩扎卢胺(160 mg/天)联合ADT或安慰剂联合ADT,按疾病体积和既往多西他赛治疗分层。
主要发现
- 仅骨转移亚组513例,骨+淋巴结转移亚组351例,仅淋巴结转移亚组154例,内脏±骨或淋巴结转移亚组128例。
- 恩扎卢胺联合ADT对比安慰剂联合ADT,仅骨转移亚组影像学进展风险HR 0.33,骨+淋巴结转移亚组HR 0.31。
- 上述亚组的次要终点也观察到相似改善。
临床怎么用
- 对于仅骨转移或骨+淋巴结转移的mHSPC患者,可考虑恩扎卢胺联合ADT治疗。
- 内脏转移患者使用恩扎卢胺联合ADT的获益可能有限,需个体化评估。
局限性
- 本研究为事后分析,非预设亚组分析,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Enzalutamide plus androgen deprivation therapy has previously been shown to improve clinical outcomes in men with metastatic hormone-sensitive prostate cancer (ARCHES; NCT02677896). Here, we assessed if and how the pattern of metastatic spread impacts efficacy of enzalutamide plus androgen deprivation therapy in men enrolled in ARCHES. MATERIALS AND METHODS: Men with metastatic hormone-sensitive prostate cancer were randomized 1:1 to enzalutamide (160 mg/day) plus androgen deprivation therapy or placebo plus androgen deprivation therapy, stratified by disease volume and prior docetaxel treatment. The primary end point was radiographic progression-free survival. Secondary end points included time to prostate specific antigen progression, initiation of new antineoplastic therapy, first symptomatic skeletal event and castration resistance. Post hoc analyses were performed by pattern of metastatic spread based on study entry imaging. RESULTS: Of the overall population with metastases identified at enrollment (1,146), the largest patient subgroups were those with bone metastases only (513) and those with bone plus lymph node metastases (351); there were fewer men with lymph node metastases only (154) and men with visceral±bone or lymph node metastases (128). Enzalutamide plus androgen deprivation therapy reduced the risk of radiographic progression vs placebo plus androgen deprivation therapy in men with bone metastases only (HR 0.33) and bone plus lymph node metastases (HR 0.31). Similar improvements in secondary end points were also observed in these subgroups. CONCLUSIONS: These findings indicate that treatment with enzalutamide plus androgen deprivation therapy provides improvements in men with bone and/or lymph node metastases but may be less effective in men with visceral patterns of spread.
引用
- Armstrong AJ, Shore ND, Szmulewitz RZ, et al. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. J Urol. 2020. PMID: 33356529. doi:10.1097/JU.0000000000001568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。